Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lukas A. Oomen"'
Autor:
Lukas A. Oomen, Leo van Buren, Odo de Weers, María Eugenia Rodríguez, Jan Poolman, Germie P. J. M. van den Dobbelsteen, Michel Beurret, Peter Hoogerhout
Publikováno v:
Vaccine. 16:1941-1949
The immunogenicity of two types of Streptococcus pneumoniae capsular polysaccharide-tetanus toxoid conjugates (PS6BTT and PS14TT) was evaluated in mice. Both conjugates induced high titres of high avidity type-specific anti-PS IgG, which include all
Autor:
Wim K. Bleeker, Matthias Peipp, Joost M. Bakker, Jan G. J. van de Winkel, Michel de Weers, Michael S. van der Veer, Kenneth C. Anderson, Paul W. H. I. Parren, Thomas Valerius, Yu-Tzu Tai, Jerry W. Slootstra, Tom Vink, Lukas A. Oomen, Tuna Mutis, Daniëlle C H Jacobs, Henk M. Lokhorst
Publikováno v:
De Weers, M, Tai, Y T, Van Der Veer, M S, Bakker, J M, Vink, T, Jacobs, D C H, Oomen, L A, Peipp, M, Valerius, T, Slootstra, J W, Mutis, T, Bleeker, W K, Anderson, K C, Lokhorst, H M, Van De Winkel, J G J & Parren, P W H I 2011, ' Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors ', Journal of Immunology, vol. 186, no. 3, pp. 1840-1848 . https://doi.org/10.4049/jimmunol.1003032
Journal of Immunology, 186(3), 1840-1848. American Association of Immunologists
Journal of Immunology, 186(3), 1840-1848. American Association of Immunologists
CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. In this study, we describe the cytotoxic mechanisms of action of dar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35212ba26b9a29a8ec88dd7dd78bdff
https://research.vumc.nl/en/publications/b6b6ee97-74dc-48a1-a8fe-33f5e327772b
https://research.vumc.nl/en/publications/b6b6ee97-74dc-48a1-a8fe-33f5e327772b
Autor:
Odo de Weers, Karen M. Reddin, Carla C. A. M. Peeters, Peter Hoogerhout, Michel Beurret, Patrick R. Lagerman, Jan Poolman, Lukas A. Oomen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07006c05c4701becb1b9c940f7068ce9
https://doi.org/10.1385/1-59259-399-2:153
https://doi.org/10.1385/1-59259-399-2:153
Autor:
Carla C. A. M. Peeters, Michel Beurret, Jan Poolman, Lukas A. Oomen, Patrick R. Lagerman, Odo de Weers, Peter Hoogerhout
It was recognized early this century that small molecules, called haptens, can be made immunogenic after conjugation to carrier proteins (1), This principle was thereafter applied successfully to improve the rmmunogenicity of (poly)saccharides (2, 3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6f59bcbdd3522dbf75d7b0ec96daae1
https://doi.org/10.1385/0-89603-334-1:111
https://doi.org/10.1385/0-89603-334-1:111
Autor:
Carla C A M, Peeters, Patrick R, Lagerman, Odo, de Weers, Lukas A, Oomen, Peter, Hoogerhout, Michel, Beurret, Jan T, Poolman, Karen M, Reddin
Publikováno v:
Methods in molecular medicine. 87
The specificity of antibody binding to pneumococcal capsular polysaccharides (Pnc PSs) measured by enzyme immunoassay (EIA) was studied by inhibition of antibody binding by homologous and heterologous PSs. We found extensive cross-reactivity of antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28bbc5ee4b2f91a5ac605554c173418f
https://europepmc.org/articles/PMC95896/
https://europepmc.org/articles/PMC95896/
Publikováno v:
Bioconjugate chemistry. 9(3)
Pneumococcal polysaccharide type 6B, 14, or 23F (35-70 kDa) was activated with cyanogen bromide and modified with cystamine. After reduction of the spacer, the thiol-containing (i.e. cysteamine-modified) polysaccharide obtained was added in a 5-10-fo
Autor:
Yu-Tzu Tai, Joost M. Bakker, Xian-Feng Li, Weihua Song, Daniëlle C H Jacobs, Sabikun Nahar, Wim K. Bleeker, Paul G. Richardson, Tom Vink, Nikhil C. Munshi, Lukas A. Oomen, Jan G. J. van de Winkel, Michel de Weers, Kenneth C. Anderson, Paul W. H. I. Parren
Publikováno v:
Blood. 114:608-608
Abstract 608 CD38 is a type II transmembrane glycoprotein highly expressed in many hematological malignancies including multiple myeloma (MM), representing a promising target for monoclonal antibody (mAb)-based targeted immunotherapy. We here investi